Atomo Diagnostics Limited (ASX:AT1)

Australia flag Australia · Delayed Price · Currency is AUD
0.0390
+0.0010 (2.63%)
At close: Mar 5, 2026
116.67%
Market Cap 31.60M
Revenue (ttm) 3.92M
Net Income (ttm) -3.98M
Shares Out 810.18M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 189,966
Average Volume 1,542,129
Open 0.0390
Previous Close 0.0380
Day's Range 0.0390 - 0.0400
52-Week Range 0.0140 - 0.0480
Beta 1.20
RSI 49.37
Earnings Date Apr 29, 2026

About Atomo Diagnostics

Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. The company offers blood test devices, such as Pascal, Curie, Galileo, Elion, and Florey under the AtomoRapid brand. It also offers HIV Rapid self-Test device; and digital health solutions. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia. [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2010
Employees 85
Stock Exchange Australian Securities Exchange
Ticker Symbol AT1
Full Company Profile

Financial Performance

In fiscal year 2025, Atomo Diagnostics's revenue was 3.79 million, a decrease of -7.20% compared to the previous year's 4.09 million. Losses were -4.97 million, -27.41% less than in 2024.

Financial Statements

News

Atomo Diagnostics Ltd (ASX:AT1) Full Year 2025 Earnings Call Highlights: Navigating Challenges ...

Atomo Diagnostics Ltd (ASX:AT1) Full Year 2025 Earnings Call Highlights: Navigating Challenges and Seizing Opportunities

6 months ago - GuruFocus